Press Releases

Press Releases

Date Title
July 23, 2021
UNITY Biotechnology to Host Investor Call with Retinal Expert Robert Bhisitkul, M.D., Ph.D., to Discuss Recent Positive Data from Phase 1 Clinical Trial of UBX1325 in Patients with Advanced Vascular Eye Disease
UNITY management team and Dr. Bhisitkul to discuss initial safety and efficacy data supporting improvements in vision and structure seen in patients treated with a single dose of UBX1325 UNITY to host conference call on July 27, 2021 , at 8:00 a.m. PT ( 11:00 a.m. ET ) SOUTH SAN FRANCISCO, Calif.
July 6, 2021
UNITY Biotechnology Announces Positive Data from Phase 1 Clinical Trial of UBX1325 in Patients with Advanced Vascular Eye Disease
Improvement in Visual Acuity and Central Subfield Thickness observed in diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD) patients treated with UBX1325 UBX1325 advances to Phase 2a study in DME patients as a potential alternative to anti-VEGF therapies UNITY to host
June 2, 2021
UNITY Biotechnology Reports Granting of New Employment Inducement Awards
SOUTH SAN FRANCISCO, Calif. , June 02, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that from May 18, 2021 through June 1, 2021 , the Compensation Committee of
May 11, 2021
UNITY Biotechnology, Inc. Reports First Quarter 2021 Financial Results and Business Updates
-  UBX1325 demonstrates favorable tolerability in Phase 1 safety study with initial evidence of relevant biological activity -  Phase 2a proof-of-concept study initiated in patients with diabetic macular edema; data expected first half of 2022 -  Cash balance sufficient to fund operations into
May 1, 2021
UNITY Biotechnology Presents UBX1325 Data Demonstrating Improvement in Retinal Vasculature and Function in Preclinical Models of Diabetic Retinopathy Eye Diseases
UBX1325’s selective elimination of senescent cells represents a novel approach for the treatment of diabetic retinopathy and macular edema Preclinical data featured in poster presentations at the ARVO 2021 Annual Meeting SOUTH SAN FRANCISCO, Calif. , May 01, 2021 (GLOBE NEWSWIRE) -- UNITY
April 28, 2021
UNITY Biotechnology to Present Preclinical Data on Clinical Candidate Molecule UBX1325 at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting
SOUTH SAN FRANCISCO, Calif. , April 28, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, will present preclinical data on its lead clinical candidate, UBX1325, at the Association
April 21, 2021
UNITY Biotechnology Reports Granting of New Employment Inducement Awards
SOUTH SAN FRANCISCO, Calif. , April 21, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that from April 6, 2021 through April 20, 2021 , the Compensation Committee
March 23, 2021
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Business Updates
SOUTH SAN FRANCISCO, Calif. , March 23, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the fourth quarter and full year ended December 31, 2020
March 11, 2021
UNITY Biotechnology Reports Granting of New Employment Inducement Award
SOUTH SAN FRANCISCO, Calif. , March 11, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that Alexander Nguyen has officially joined UNITY as general counsel, and
March 8, 2021
UNITY Biotechnology Announces Appointment of Alexander Nguyen as General Counsel
SOUTH SAN FRANCISCO, Calif. , March 08, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that Alexander Nguyen has been appointed general counsel.
Displaying 11 - 20 of 25